Avandia Trial Re-Adjudication Beyond FDA’s Abilities, Agency Officials Say

FDA had only a portion of the information needed to conduct a re-adjudication, Bob Temple tells advisory committee during the first of a two-day discussion of rosiglitizone’s cardiovascular safety.